Latest Gut Health News

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

The a2 Milk Company is expanding its strategic partnership with China State Farm to include English label infant milk formula products, starting with a2 Genesis™ in early 2026. This move aims to strengthen distribution control and capitalize on China’s booming infant formula market.

Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.

Bega Cheese delivered a robust FY2025 performance with a 23% rise in normalised EBITDA and a 74% jump in profit after tax, underpinned by strategic brand growth and operational efficiencies. The company raised its FY2026 EBITDA guidance and outlined ambitious plans for international expansion and product innovation.

Bega Cheese Limited reported robust FY2025 results marked by strategic site consolidations, innovation-led growth, and a strong financial position, setting the stage for an optimistic FY2026.

EVE Health Group has appointed Dr Fiona Cousins as the inaugural member of its Scientific Advisory Board, reinforcing its commitment to advancing treatments for dysmenorrhoea and endometriosis ahead of the commercial launch of Dyspro™.

BPH Global has completed an 18-week R&D collaboration with Singapore Polytechnic, developing two innovative green seaweed kefir beverages that combine health benefits with commercial promise.

Biome Australia has secured key distribution partnerships with Mecca and Go Vita, launching its Activated Probiotics range into premium beauty and health food channels across Australia.

Elixinol Wellness has launched its Healthy Chef Protein Water range, entering Australia’s rapidly expanding $499 million protein supplements market with a clean-label, functional beverage lineup.

Hydralyte USA reported an 8.5% rise in Q2 FY25 net sales, driven by strong May performance and improved margins, while preparing to launch new brain and gut health products.

Microba Life Sciences reports record Q4 FY25 microbiome test sales in Australia and the UK, underpinned by landmark clinical studies and a $14.5 million capital raise. The company is transitioning away from legacy products to focus on high-value diagnostics, positioning for sustained growth in FY26.

Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.